Press releaseGlobe Newswire
Ultragenyx Pharmaceutical
RARE · NASDAQ
$16.02+$0.95 (+6.30%)TodayMarket closed ·
Prev close $15.07
Latest news
- Press releaseGlobe Newswire
Ultragenyx Enters into Agreement to Sell Rare Pediatric Disease Priority Review Voucher for $210 Million
- Press releaseGlobe Newswire
Ultragenyx Announces Marketing Authorisation Application (MAA) Submission to the European Medicines Agency (EMA) for the First Investigational Gene Therapy for MPS IIIA (Sanfilippo Syndrome Type A)
- Press releasePRNewswire
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Ultragenyx Pharmaceutical Inc. - RARE
- Press releaseGlobe Newswire
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Ultragenyx Pharmaceutical Inc. - RARE
- NewsVandana Singh
Ultragenyx Wins First Sanfilippo Approval As Analyst Keeps Ratings Modest
- NewsMohd Haider
Ultragenyx Pharmaceutical (RARE) Stock Jumps After Hours: Here's Why It Is Trending
- Press releaseGlobe Newswire
Ultragenyx Announces Approval of FAYUVI™ Gene Therapy, the First-Ever FDA-Approved Treatment for Sanfilippo Syndrome Type A (MPS IIIA)
- Press releasePRNewswire
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Ultragenyx Pharmaceutical Inc. - RARE
- Press releaseGlobe Newswire
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Ultragenyx Pharmaceutical Inc. - RARE
- NewsErica Kollmann
QUICK SPARK: Pharma Bro Martin Shkreli Says Ultragenyx Should Be M&A Target
- NewsAvi Kapoor
Gold Jumps 3%; ISM Services PMI Rises In August
- NewsAvi Kapoor
Nasdaq Gains Over 200 Points; US Weekly Jobless Claims Edge Higher
- NewsVandana Singh
Ultragenyx Forced To Cut Costs After Disappointing Phase 3 Results
- NewsAvi Kapoor
NetApp, Hewlett Packard Enterprise And Other Big Stocks Moving Lower In Thursday’s Pre-Market Session
- News
Market-Moving News for September 3rd
- NewsAvi Kapoor
Why Snowflake Shares Are Trading Higher By Over 24%; Here Are 20 Stocks Moving Premarket
- News
12 Health Care Stocks Moving In Wednesday's After-Market Session
- Press releaseGlobe Newswire
Ultragenyx Announces Phase 3 Aspire results in Angelman Syndrome
- NewsVandana Singh
Ultragenyx FDA-Approved Treatment Shows Sustained Reduction in Cornstarch Intake
- News
10 Health Care Stocks Whale Activity In Today’s Session
- NewsVandana Singh
Ultragenyx Nabs FDA Nod for First Gene Therapy
- Press releaseGlobe Newswire
Ultragenyx Announces U.S. FDA Approval of GENGLYCOS™ Gene Therapy, the First-Ever FDA-Approved Treatment Designed to Treat the Underlying Cause of Glycogen Storage Disease Type Ia (GSDIa)
- Press releaseGlobe Newswire
Ultragenyx Reports Second Quarter 2026 Financial Results and Corporate Update
- Press releaseGlobe Newswire
Ultragenyx Releases 2025 Impact Report Emphasizing Commitment to Rare Disease Patients, Innovation, and Global Impact
- NewsPiero Cingari
Small Caps Near Record Highs, Robinhood Rallies 12%: Stock Market Today
- NewsAvi Kapoor
Jabil Posts Upbeat Q3 Results, Joins Uniqure, Braiin And Other Big Stocks Moving Higher On Wednesday
- Press releasePRNewswire
Kuehn Law Encourages Investors of Ultragenyx Pharmaceutical Inc. to Contact Law Firm
- News
Ultragenyx Pharmaceutical Q1 2026 Earnings Call Transcript
- News
Earnings Scheduled For May 5, 2026
- Press releaseGlobe Newswire
Ultragenyx Pharmaceutical Inc. Class Action: Levi & Korsinsky Reminds Ultragenyx Investors of the Pending Class Action Lawsuit with a Lead Plaintiff Deadline of April 6, 2026 – RARE
- Press releaseGlobe Newswire
ULTRAGENYX URGENT DEADLINE: Bragar Eagel & Squire, P.C. Reminds Ultragenyx (NASDAQ:RARE) Investors of the April 6th Lead Plaintiff Deadline and Urges Investors to Contact the Firm
- Press releaseBusiness Wire
RARE FINAL DEADLINE ALERT: Faruqi & Faruqi, LLP Reminds Ultragenyx Pharmaceutical (RARE) Investors of Securities Class Action Deadline on April 6, 2026
- Press releasePRNewswire
RARE Investors Have Opportunity to Lead Ultragenyx Pharmaceutical Inc. Securities Fraud Lawsuit with the Schall Law Firm
- Press releasePRNewswire
RARE SHAREHOLDER ALERT: Faruqi & Faruqi, LLP Reminds Ultragenyx Pharmaceutical (RARE) Investors of Securities Class Action Deadline on April 6, 2026
- Press releaseBusiness Wire
Ultragenyx 72 Hour Deadline Alert: Kahn Swick & Foti, LLC Reminds Investors With Losses In Excess Of $100,000 of Deadline in Class Action Lawsuit Against Ultragenyx Pharmaceutical Inc. - RARE
- Press releaseBusiness Wire
RARE Deadline: Rosen Law Firm Urges Ultragenyx Pharmaceutical Inc. (NASDAQ: RARE) Stockholders with Losses in Excess of $100K to Contact the Firm for Information About Their Rights
- Press releasePRNewswire
DEADLINE NEXT WEEK: Berger Montague Advises Ultragenyx Pharmaceutical Inc. (NASDAQ: RARE) Investors to Contact the Firm Before April 6, 2026
- Press releaseGlobe Newswire
RARE SHAREHOLDER REMINDER: Faruqi & Faruqi, LLP Reminds Ultragenyx Pharmaceutical (RARE) Investors of Securities Class Action Deadline on April 6, 2026
- Press releaseGlobe Newswire
Ultragenyx Shareholder Alert: ClaimsFiler Reminds Investors With Losses In Excess Of $100,000 Of Lead Plaintiff Deadline In Class Action Lawsuit Against Ultragenyx Pharmaceutical Inc. - RARE
- Press releasePRNewswire
INVESTOR ALERT: Pomerantz Law Firm Reminds Investors with Losses on their Investment in Ultragenyx Pharmaceutical Inc. of Class Action Lawsuit and Upcoming Deadlines - RARE
- Press releasePRNewswire
Levi & Korsinsky Reminds Shareholders of a Lead Plaintiff Deadline of April 6, 2026 in Ultragenyx Lawsuit - RARE
- Press releaseGlobe Newswire
Ultragenyx Pharmaceutical Inc. Notice of April 6, 2026 Application Deadline for Class Action Lawsuit - Contact Lewis Kahn, Esq. at Kahn Swick & Foti, LLC, Before Application Deadline
- Press releaseGlobe Newswire
INVESTOR ALERT: Pomerantz Law Firm Reminds Investors with Losses on their Investment in Ultragenyx Pharmaceutical Inc. of Class Action Lawsuit and Upcoming Deadlines – RARE
- Press releasePRNewswire
LEVI & KORSINSKY, LLP: FRAUD-ON-THE-MARKET DOCTRINE UNDERPINS ULTRAGENYX PHARMACEUTICAL SECURITIES CLASS ACTION
- Press releaseGlobe Newswire
Levi & Korsinsky, LLP: Section 10(b) and Rule 10b-5 Claims Filed Against Ultragenyx Pharmaceutical
- Press releasePRNewswire
LEVI & KORSINSKY, LLP: MANAGEMENT CONFIDENCE REPRESENTATIONS CHALLENGED IN ULTRAGENYX PHARMACEUTICAL SECURITIES ACTION
- NewsAvi Kapoor
IBM To Rally More Than 23%? Here Are 10 Top Analyst Forecasts For Monday
- NewsAvi Kapoor
Why OceanFirst Financial Shares Are Trading Lower By Around 7%? Here Are Other Stocks Moving In Tuesday's Mid-Day Session
- NewsAvi Kapoor
CapsoVision, ACM Research And Other Big Stocks Moving Higher On Tuesday
- NewsAvi Kapoor
State Street To Rally Around 14%? Here Are 10 Top Analyst Forecasts For Tuesday
- NewsAvi Kapoor
Why Ultragenyx Pharmaceutical Shares Are Trading Lower By Around 42%? Here Are Other Stocks Moving In Monday's Mid-Day Session
- NewsAvi Kapoor
Silver Tumbles 8%; Society Pass Shares Spike Higher
- NewsAvi Kapoor
Dow Falls Over 100 Points; US Pending Home Sales Rise In November
- NewsAvi Kapoor
Crude Oil Down Over 2%; Delta Air Lines Posts Upbeat Earnings
- NewsAvi Kapoor
US Stocks Mixed; Initial Jobless Claims Fall
Information on this page is provided for informational purposes only and is not a recommendation to buy, sell or hold any security. Investing involves risk, including possible loss of principal. Market data is delayed at least 15 minutes and is provided without warranty. Analyst ratings, price targets and company data come from third-party sources. Past performance does not guarantee future results.